azelnidipine has been researched along with dihydropyridines in 180 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.11) | 18.7374 |
| 1990's | 7 (3.89) | 18.2507 |
| 2000's | 77 (42.78) | 29.6817 |
| 2010's | 88 (48.89) | 24.3611 |
| 2020's | 6 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Koike, H; Miyamoto, M; Oizumi, K | 2 |
| Koike, H; Miyake, S; Miyamoto, M; Nishino, H; Oizumi, K; Sada, T; Shiga, H | 1 |
| Fukami, M; Fukushige, J; Koike, H; Miyamoto, M; Nishino, H; Oizumi, K | 1 |
| Kimura, T; Koike, H; Miyamoto, M; Nishino, H; Oizumi, K; Sada, T | 1 |
| Kobayashi, T; Masumoto, K; Oizumi, K; Takeyasu, A | 1 |
| Frasier, L; Koike, H; Miyamoto, M; Oizumi, K; Yagil, Y | 1 |
| Hoshi, K; Ichihara, K; Satoh, K; Yamamoto, A | 1 |
| Arita, M; Hashizume, T; Nishio, I; Tanigawa, K; Yamamoto, H | 1 |
| Abe, K; Kanazawa, M; Kohzuki, M; Kurosawa, H; Minami, N; Saito, T; Yasujima, M; Yoshida, K | 1 |
| Hirai, A; Ichikawa, S; Kanada, S; Kuramoto, K; Nakachi, T; Ogihara, T | 1 |
| Scott, LJ; Wellington, K | 1 |
| Sada, T; Saito, H | 1 |
| Cui, TX; Horiuchi, M; Iwai, M; Jinno, T; Li, JM; Li, Z; Liu, HW; Ogihara, T; Rakugi, H | 1 |
| Hanawa, N; Sano, N; Takikawa, H | 1 |
| Imaizumi, T; Inagaki, Y; Nakamura, K; Yamagishi, S | 1 |
| Cui, TX; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Suzuki, J; Tsuda, M | 1 |
| Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Yoshida, K; Yoshiyama, M | 1 |
| Inoue, H; Nakamura, K; Yamagishi, S | 1 |
| Horiuchi, M; Ide, A; Iwai, M; Li, JM; Li, Z; Min, LJ; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T | 1 |
| Abe, Y; Hara, T; Hitomi, H; Kimura, S; Kiyomoto, H; Kohno, M; Kondo, N; Miyatake, A; Moriwaki, K; Nishiyama, A; Rahman, M; Sun, GP; Yamamoto, T | 1 |
| Inoue, H; Takeuchi, M; Yamagishi, S | 1 |
| Inoue, H; Kikuchi, S; Matsui, T; Nakamura, K; Yamagishi, S | 1 |
| Iida, H; Imuta, H; Jo, T; Kishida, S; Ma, J; Meguro, K; Morita, T; Nagai, R; Nakajima, T; Oonuma, H; Takano, H; Wang, GQ | 1 |
| Abe, Y; Fan, YY; Fujisawa, Y; Kimura, S; Kiyomoto, H; Kohno, M; Nishiyama, A; Rahman, M; Shokoji, T; Sun, GP | 1 |
| Kawabata, K; Urasaki, Y | 1 |
| Egashira, K; Endo, Y; Hirouchi, Y; Kitajima, S; Kohjimoto, Y; Li, XH; Nakano, K; Sunagawa, K; Tada, H | 1 |
| Ichikawa, H; Katada, K; Kokura, S; Kon, T; Manabe, H; Naito, Y; Nakabe, N; Shimozawa, M; Yoshida, N; Yoshikawa, T | 1 |
| Ding, L; Li, L; Ma, P | 1 |
| Chen, R; Horiuchi, M; Ide, A; Iwai, M; Iwanami, J; Mogi, M; Tomochika, H; Tomono, Y | 1 |
| Ito, T; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Ogawa, H; Tanaka, T; Tokutomi, Y; Yamamoto, E; Yamashita, T | 1 |
| Hayashi, K; Iigaya, K; Kumagai, H; Onami, T; Takimoto, C | 1 |
| Inoue, T; Kobayashi, K; Nakamoto, H; Shoda, J; Suzuki, H | 1 |
| Chen, R; Horiuchi, M; Iwai, M; Li, HS; Li, JM; Min, LJ; Mogi, M; Shiuchi, T; Suzuki, J; Tomochika, H; Tomono, Y; Tsuda, M; Wu, L | 1 |
| Aishima, M; Ito, Y; Teramoto, N; Tomoda, T; Zhu, HL | 1 |
| Kurabayashi, M; Nakamura, T; Saito, T; Saito, Y | 1 |
| Shimokado, K; Takahashi, K; Yoshida, M | 1 |
| Hirooka, Y; Kimura, Y; Sagara, Y; Sunagawa, K | 1 |
| Yamagishi, T | 1 |
| Arimoto, T; Harada, M; Kitahara, T; Koyama, Y; Kubota, I; Niizeki, T; Sasaki, T; Shishido, T; Suzuki, S; Takahashi, H; Takeishi, Y | 1 |
| Fukazawa, I; Kawabata, K; Samata, N; Uchida, E; Uchida, N; Urasaki, Y; Yasuhara, H | 1 |
| Kanda, T; Matsumoto, M; Morimoto, S; Murai, H; Nakahashi, T; Nishino, T; Nomura, K; Okaishi, K; Okuro, M; Takahashi, T | 1 |
| Enomoto, S; Iwao, H; Izumi, Y; Kusuyama, T; Matsumoto, R; Nishiya, D; Omura, T; Takeuchi, K; Yoshiyama, M | 1 |
| Egashira, K; Gang, Z; Iwata, E; Miyagawa, M; Nakano, K; Ohtani, K; Sunagawa, K | 1 |
| Akashi, H; Aoyagi, S; Hiromatsu, S; Kato, S; Yokokura, H | 1 |
| Nakamoto, M; Ohya, Y; Sakima, A; Takishita, S; Yamazato, M | 1 |
| Fukuoka, T; Higaki, J; Manabe, S; Okura, T | 1 |
| Inoue, T; Kawagoe, Y; Koide, H; Nakamura, T; Node, K; Sugaya, T; Suzuki, T; Ueda, Y | 1 |
| Eguchi, K; Fukuda, T; Hoshide, S; Ishikawa, J; Kario, K; Numao, T; Shimada, K; Tomizawa, H | 1 |
| Fuse, E; Kobayashi, H; Kuwabara, T; Mimura, N; Sugiyama, Y; Ushiki, J | 1 |
| Fujitani, Y; Hirose, T; Kanazawa, A; Kawamori, R; Ohmura, C; Sakai, K; Shimizu, T; Uchino, H; Watada, H | 1 |
| Abe, K; Deguchi, K; Hayashi, T; Kamiya, T; Lukic-Panin, V; Sehara, Y; Tsuchiya, A; Yamashita, T; Zhang, H | 1 |
| Wang, N; Xu, R; Yan, F; Ye, L | 1 |
| Ito, S; Kawano, T; Koshiba, K; Mikawa, J; Nada, T; Nomura, M | 1 |
| Guo, Q; Ito, O; Kanazawa, M; Kohzuki, M; Kurosawa, H; Minami, N; Mori, N; Nagasaka, M | 1 |
| Matsumoto, C; Shiina, K; Tomiyama, H; Yamada, J; Yamashina, A; Yoshida, M | 1 |
| Fukumoto, Y; Ito, K; Nawata, J; Onoue, N; Shimokawa, H; Sugimura, K; Tada, T; Wang, H; Zhulanqiqige, D | 1 |
| Ito, S; Mori, T; Nako, K; Ogawa, S | 1 |
| Abe, K; Deguchi, K; Kamiya, T; Lukic-Panin, V; Sehara, Y; Yamashita, T; Zhang, H | 1 |
| Fan, HW; Hu, Q; Ji, HJ; Xiao, DW; Zhou, XH; Zhu, YB; Zou, JJ | 1 |
| Iwamoto, Y; Katayama, S; Kawamori, R; Kuramoto, K; Saito, I | 1 |
| Aoyagi, K; Hirayama, A; Koyama, A; Nagase, S; Oteki, T; Ueda, A | 1 |
| Fujiwara, N; Inoue, T; Kawagoe, Y; Koide, H; Nakamura, T; Node, K; Sugaya, T; Ueda, Y | 1 |
| Abe, K; Funakoshi, S; Furusu, A; Harada, T; Kohno, S; Koji, T; Kurashige, T; Miyazaki, M; Nakazawa, M; Nakazawa, Y; Obata, Y; Xia, Z | 1 |
| Araki, S; Hirooka, Y; Kishi, T; Koga, Y; Konno, S; Sunagawa, K | 1 |
| Furuno, M; Higaki, J; Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Mogi, M; Okayama, H; Senba, I; Tomono, Y | 1 |
| Hatazawa, J; Hougaku, H; Kajimoto, K; Kato, H; Kimura, Y; Kitagawa, K; Oku, N; Sakaguchi, M; Sakoda, S; Tanaka, M | 1 |
| Ikeda, K; Inada, Y; Isaka, T; Tajima, N; Takada, Y; Tojo, K | 1 |
| Chiba, S; Fujisawa, M; Koike, H; Yorikane, R | 1 |
| Abe, T; Aizawa, Y; Fuse, I; Narita, M; Takahashi, M | 1 |
| Adachi, T; Aizawa, Y; Chinushi, M; Hirono, S; Ito, M; Kodama, M; Mitsuma, W; Nakazawa, M; Okamura, K; Tanaka, K | 1 |
| Abe, K; Deguchi, K; Kamiya, T; Nagotani, S; Yamashita, T | 1 |
| Cheng, XW; Harada, K; Hirashiki, A; Inoue, A; Jin, Z; Kuzuya, M; Murohara, T; Nagata, K; Obata, K; Okumura, K; Shi, GP; Takeshita, K; Unno, K; Yokota, M | 1 |
| Du, J; Fan, YY; Fu, H; Fujisawa, Y; Hitomi, H; Hosomi, N; Kimura, S; Kiyomoto, H; Kohno, M; Lu, XM; Nagai, Y; Nakano, D; Nishiyama, A; Ohmori, K | 1 |
| Fujimoto, S; Horike, H; Kashihara, N; Nagasu, H; Sasaki, T; Satoh, M | 1 |
| Eguchi, K; Ishikawa, J; Kario, K; Matsui, Y; Miyashita, H; O'Rourke, MF; Shimada, K | 1 |
| Blacher, J; Protogerou, A; Safar, ME | 1 |
| Ishii, K; Ito, H; Iwakura, K; Nagano, T; Nakamura, F; Takiuchi, S | 1 |
| Akabane, T; Ishimitsu, T; Masuda, T; Matsuoka, H; Minami, J; Numabe, A; Okamura, A | 1 |
| Ishida, A; Ito, O; Kanazawa, M; Kohzuki, M; Kurosawa, H; Lu, H; Ootaka, T; Sasaki, Y; Sato, T; Tufescu, A | 1 |
| Arakawa, K; Kuramoto, K; Tanigawara, Y; Yoshihara, K | 1 |
| Geot, WM; Horikoshi, S; Suzuki, Y; Takahashi, H; Tanifuji, C; Tomino, Y | 1 |
| Daida, H; Fujiwara, Y; Inoue, K; Kawamura, M; Kojima, T; Kurata, T; Miyauchi, K; Nakazato, Y; Okazaki, S; Sumiyoshi, M; Suwa, S; Tanimoto, K; Yamagami, S; Yokoyama, K; Yokoyama, T | 1 |
| Kuramoto, K; Ogihara, T; Saruta, T; Shimada, K | 2 |
| Hirano, T; Okamoto, S; Shiraishi, S; Tomiguchi, S; Uchino, M; Watanabe, M | 1 |
| Ishizaka, T; Iwasaki, H; Kise, H; Mitsumori, Y; Nakamura, Y; Sugiyama, A; Takahara, A | 1 |
| Hirooka, Y; Sunagawa, K | 1 |
| Akashi, H; Aoyagi, S; Hiromatsu, S; Nakamura, E; Onitsuka, S; Tanaka, A | 1 |
| Ando, C; Inoue, Y; Kakuma, T; Kodama, S; Miyoshi, K; Niimura, H; Nonaka, Y; Okamura, K; Sumi, S; Tsuchiya, Y; Urata, H; Yamanouchi, Y | 1 |
| Hosoya, M; Ohashi, J; Sawada, A; Shimokawa, H; Takaki, A | 1 |
| Doi, M; Hirohata, S; Kaji, Y; Kamikawa, S; Kusachi, S; Miyoshi, T; Ninomiya, Y; Ogawa, H; Sakane, K; Usui, S | 1 |
| Araki, E; Goto, R; Kondo, T; Miyamura, N; Ono, K; Sonoda, K; Takaki, Y; Yasuda, T; Yatsuda, R | 1 |
| Inoue, T; Komoda, H; Node, K | 1 |
| Kadoya, H; Matsuda, J; Namba, T; Takeji, M; Yamamoto, T; Yamauchi, A | 1 |
| Du, Y; Li, F; Li, L; Xue, N; Zhang, K | 1 |
| Hisamatsu, K; Ito, H; Kajiya, M; Kusano, KF; Matsubara, H; Miura, A; Miura, D; Miura, R; Morita, H; Nagase, S; Nakamura, K; Ohe, T | 1 |
| Cao, B; Jia, S; Li, H; Lin, Y; Qu, P; Wang, M; Wu, F; Zhao, X | 1 |
| Maeda, S; Matsui, T; Takeuchi, M; Yamagishi, S | 1 |
| Kain, V; Kumar, S; Puranik, AS; Sitasawad, SL | 1 |
| Eguchi, K; Ishikawa, J; Kario, K; Matsui, Y; Shimada, K | 1 |
| Eguchi, K; Ishikawa, J; Kario, K; Matsui, Y; O'Rourke, MF; Shimada, K | 1 |
| Kashihara, N; Nagasu, H; Sasaki, T; Satoh, M; Tomita, N; Yorimitsu, D | 1 |
| Palatini, P | 1 |
| Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Takeuchi, M; Ueda, Y; Yamagishi, S | 1 |
| Daida, H; Fujiwara, Y; Hiro, T; Inoue, K; Kawamura, M; Kojima, T; Komiyama, N; Kurata, T; Miyauchi, K; Nakazato, Y; Okazaki, S; Sumiyoshi, M; Suwa, S; Tamura, H; Tanimoto, K; Yamagami, S; Yokoyama, K; Yokoyama, T | 1 |
| Amirghofran, Z; Bagheri, M; Jahromi, BM; Mirkhani, H; Noorafshan, A; Solhjou, Z; Zamani, A | 1 |
| Ichihara, K; Kano, S; Komatsu, K; Satoh, K | 1 |
| Ando, K; Fujita, T; Haneda, M; Ito, S; Kashihara, N; Kishimoto, J; Nangaku, M; Node, K; Shimosawa, T | 1 |
| Abe, M; Maruyama, N; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M | 1 |
| Hayashi, K | 1 |
| Horiguchi, N; Ichikawa, T; Izumi, T; Kakizaki, S; Kishimoto, K; Mori, M; Ohyama, T; Sato, K; Takagi, H; Yamazaki, Y | 1 |
| Saito, Y; Takami, T | 2 |
| Daida, H; Fukao, K; Hiki, M; Hirose, K; Kiyanagi, T; Kume, A; Kurata, T; Matsumori, R; Miyazaki, T; Ohsaka, H; Shimada, K | 1 |
| Kain, V; Kumar, S; Sitasawad, SL | 1 |
| Fujimoto, S; Kashihara, N; Nagasu, H; Sasaki, T; Satoh, M; Tomita, N | 1 |
| Kano, K; Kishi, N; Konse, T; Ohashi, J; Takahashi, F; Ueyama, E | 1 |
| Ishikura, F; Takano, Y; Ueyama, T | 1 |
| Hirooka, Y; Kishi, T; Ogawa, K; Shinohara, K; Sunagawa, K; Utsumi, H; Yasukawa, K | 1 |
| Arakawa, K; Jinnouchi, H; Jinnouchi, T; Kim-Mitsuyama, S; Matsui, K; Ogawa, H | 2 |
| Inoue, T; Kikuta, T; Kojima, E; Nodaira, Y; Ohno, Y; Okayama, M; Seto, T; Sueyoshi, K; Suzuki, H; Takane, H; Takenaka, T; Watanabe, Y | 1 |
| Hoshide, S; Ishikawa, J; Kario, K; Matsui, Y; O'Rourke, MF; Shimada, K | 1 |
| Bilo, G; Parati, G | 1 |
| Ishikawa, J; Kario, K; Matsui, Y; O'Rourke, MF; Shimada, K | 1 |
| Daikuhara, H; Ishida, T; Kikuchi, F | 1 |
| Li, D; Ren, G; Wang, J; Wang, M; Yang, C | 1 |
| Rich, MW | 1 |
| Iso, T; Kawai-Kowase, K; Kurabayashi, M; Shimizu, T; Tanaka, T | 1 |
| Fukumoto, Y; Hosoya, M; Nakajima, S; Noda, K; Ohashi, J; Shimokawa, H | 1 |
| Daida, H; Miyauchi, K | 1 |
| Aihara, M; Baba, Y; Ikezawa, Y; Ikezawa, Z; Imai, M; Kanbara, T; Matsukura, S; Moriya, M | 1 |
| Fujisawa, M; Koike, H; Matsuoka, Y; Ueno, K; Yorikane, R | 1 |
| Hiramatsu, K; Kario, K; Komiya, M; Sato, Y; Shimada, K; Shiosakai, K; Shirayama, M; Takahashi, M | 1 |
| Hiramatsu, K; Kario, K; Komiya, M; Shimada, K; Shiosakai, K; Shirayama, M; Takahashi, M; Uehara, Y | 1 |
| Hirata, Y; Kitagawa, T; Kurobe, H; Matsuoka, Y; Maxfield, MW; Sata, M; Sugasawa, N | 1 |
| Dohi, Y; Hirota, H; Isaka, N; Ito, M; Kato, T; Kimura, G; Kojima, M; Machida, H; Makino, K; Miyagawa, K; Mizubayashi, R; Mizuno, O; Nakatani, K; Okamoto, S; Okubo, S; Okura, T; Takeuchi, M | 1 |
| Bahrudin, U; Endo, R; Hasegawa, A; Hisatome, I; Ikeda, N; Li, P; Maharani, N; Morikawa, K; Ninomiya, H; Rifqi, S; Sakata, S; Shirayoshi, Y; Sobirin, MA; Utami, SB; Yamamoto, K | 1 |
| Iribe, G; Ito, H; Kaihara, K; Naruse, K | 1 |
| Gao, G; He, GW; Jing, WB; Liu, XC; Yang, Q | 1 |
| Furusu, A; Kohno, S; Koji, T; Miyazaki, T; Nishino, T; Obata, Y; Sato, Y; Uramatsu, T | 1 |
| Masroor, S | 1 |
| Amaya, N; Arakawa, K; Fukuoka, Y; Ishida, K; Lee, JD; Morishita, T; Nakano, A; Tada, H; Uzui, H | 1 |
| Cheng, J; Hamada, T; Hirata, S; Hisatome, I; Igawa, O; Kato, M; Kuwabara, M; Miyazaki, S; Mizuta, E; Moriwaki, Y; Ninomiya, H; Nosaka, Y; Ogino, K; Ohtahara, A; Yamamoto, K; Yamamoto, Y; Yoshida, A | 1 |
| Ikeda, U; Izawa, A; Koyama, J; Miyashita, Y; Motoki, H; Takahashi, M; Tomita, T | 1 |
| Abe, K; Deguchi, K; Hishikawa, N; Ikeda, Y; Kono, S; Kurata, T; Liu, W; Omote, Y; Yamashita, T | 1 |
| Furusho, H; Hamaoka, T; Ikeda, T; Inomata, J; Kaneko, S; Kobayashi, D; Murai, H; Sugiyama, Y; Takamura, M; Takata, S; Usui, S | 1 |
| Ito, S; Komatsubara, AT; Kyotani, Y; Nagayama, K; Ozawa, K; Tsuji, Y; Yoshizumi, M; Zhao, J | 1 |
| Izumikawa, Y; Kato, H; Kojima, K; Kubo, E; Nagura, M; Nosaka, H; Shima, T; Shimada, M; Shiraishi, T; Tanemoto, M; Tomioka, S; Uchida, S; Ueda, S; Yano, H | 1 |
| Imanishi, M; Kitabayashi, C; Kobori, H; Kohno, M; Konishi, Y; Masaki, T; Mori, H; Morikawa, T; Nishiyama, A; Rafiq, K | 1 |
| Date, M; Ishii, K; Ito, H; Iwakura, K; Nagano, T; Nakamura, F; Takiuchi, S | 1 |
| Daida, H; Miyauchi, K; Shimada, K | 1 |
| Fang, Z; Gao, Y; Li, B; Liu, D; Lou, H; Wang, H; Zhao, H; Zhu, B | 1 |
| Kamiya, A; Kawada, T; Miyazaki, S; Shimizu, S; Sugimachi, M; Turner, MJ; Yamamoto, H | 1 |
| Kawasaki, S; Kimura, M; Kondo, Y; Nakamura, A; Takihata, M; Terauchi, Y | 1 |
| Hamamoto, S; Hashiramoto, M; Kaku, K; Kamei, S; Kanda-Kimura, Y; Kaneto, H; Kimura, T; Matsuda, M; Mune, T; Obata, A; Shimoda, M; Tatsumi, F; Tawaramoto, K | 1 |
| Kushiro, T; Matsushita, Y; Okutani, Y; Sagawa, K; Saito, I; Sato, Y; Tanaka, Y; Tanigawa, M | 1 |
| Asai, S; Nakayama, T; Nishida, Y; Susa, N; Takahashi, Y; Yada, Y | 1 |
| Bisenieks, E; Duburs, G; Gall Troselj, K; Krauze, A; Poikans, J; Velena, A; Zarkovic, N | 1 |
| Hano, T; Iwane, N; Kawabe, T; Koike, Y; Nishihara, K | 1 |
| Fukui, M; Hasegawa, G; Matsumoto, S; Nakamura, N; Oyabu, C; Tanaka, M; Ushigome, E; Ushigome, H; Yamazaki, M; Yokota, I | 1 |
| Guo, W; Lv, J; Pan, Y; Pang, W; Wang, J; Yang, C | 1 |
| Jiang, D; Kato, J; Kawagoe, Y; Kitamura, K; Kuwasako, K | 1 |
| Dobashi, S; Fujii, T; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T | 2 |
| Kimura, A; Kondo, T; Nishimura, Y; Ozawa, K; Tanaka, T; Yoshizumi, M; Zhao, J | 1 |
| Komoda, H; Nishikido, T; Node, K; Oyama, JI; Shiraki, A | 1 |
| Bassossy, HME; Fahmy, A; Hassan, NA; Mahmoud, MF | 1 |
| Askarova, S; Lee, JC; Ridgley, DM; Sun, GY; Teng, T; Tsoy, A | 1 |
| Abd El Rehim, RT; El-Gazayerly, ON; El-Helaly, SN; Rashad, AA | 1 |
| Avari, JG; Gaikwad, SS | 1 |
| Okamura, K; Shirai, K; Takamiya, Y; Urata, H; Yano, Y | 1 |
| Abd El Rehim, RT; El-Gazayerly, ON; Nageeb El-Helaly, S; Rashad, AA | 1 |
| Ishii, K; Kurakami, K; Nasu, F; Norota, I; Obara, Y; Okamoto, Y; Yamaguchi, H | 1 |
| Chen, J; Dong, Q; Gao, Y; Jiao, L; Qian, Y; Qiu, L; Sun, Y; Wang, H; Wu, Y; Zhai, W; Zhao, W; Zheng, WV; Zhou, X | 1 |
| Cao, R; Chen, X; Dai, Q; Guo, X; Li, W; Li, Y; Liu, M; Wang, Z; Xu, Y; Yan, Y; Yang, X; Yin, J; Zhong, W | 1 |
| Akimoto, S; Kawabata, K; Kotake, Y; Miyara, M; Nishi, H; Sakaue, M | 1 |
| Maiti, R; Maji, S; Pal, D | 1 |
8 review(s) available for azelnidipine and dihydropyridines
| Article | Year |
|---|---|
Azelnidipine.
Topics: Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Calcium Channels, L-Type; Dihydropyridines; Hemodynamics; Humans; Hypertension; Randomized Controlled Trials as Topic | 2003 |
Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Heart Rate; Humans; Hypertension | 2003 |
[Novel actions of calcium channel blockers].
Topics: Amlodipine; Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Depression; Dihydropyridines; Evidence-Based Medicine; Heart Rate; Humans; Hypertension; Kidney Diseases; Proteinuria; Sympathetic Nervous System | 2006 |
Gene and stem cell therapy in ischemic stroke.
Topics: Animals; Antioxidants; Azetidinecarboxylic Acid; Biliverdine; Brain Ischemia; Dihydropyridines; Disease Models, Animal; Genetic Therapy; Glial Cell Line-Derived Neurotrophic Factor; Humans; Models, Biological; Neuroprotective Agents; Stem Cell Transplantation | 2009 |
[Calcium antagonists: current and future applications based on new evidence. Calcium channel blockers and autonomic nervous system].
Topics: Amlodipine; Antihypertensive Agents; Antioxidants; Autonomic Nervous System; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Heart Rate; Humans | 2010 |
Azelnidipine and glucose tolerance: possible indications and treatment selection for hypertensive patients with metabolic disorders.
Topics: Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Glucose Intolerance; Humans; Hypertension; Metabolic Diseases; Renin-Angiotensin System | 2015 |
1,4-Dihydropyridine Derivatives: Dihydronicotinamide Analogues-Model Compounds Targeting Oxidative Stress.
Topics: Amlodipine; Animals; Antioxidants; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cattle; Dihydropyridines; Epithelial Cells; Humans; Hydrogen; Lipoproteins, LDL; Mice; Microsomes; Mitochondria; Niacinamide; Nifedipine; Nitrobenzenes; Oxidants; Oxidative Stress; Piperazines | 2016 |
Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension | 2023 |
48 trial(s) available for azelnidipine and dihydropyridines
| Article | Year |
|---|---|
A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Cross-Over Studies; Dihydropyridines; Double-Blind Method; Exercise; Female; Humans; Hypertension; Male; Middle Aged; Placebos; Sympathetic Nervous System; Vascular Resistance | 1999 |
Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure.
Topics: Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Dihydropyridines; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Physicians' Offices | 2003 |
Azelnidipine. CS 905, Calblock, RS 9054.
Topics: Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Double-Blind Method; Drugs, Investigational; Hypertension; Rats; Rats, Inbred SHR | 2003 |
Determination of azelnidipine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry.
Topics: Administration, Oral; Adult; Asian People; Azetidinecarboxylic Acid; Calcium Channel Blockers; China; Chromatography, High Pressure Liquid; Dihydropyridines; Drug Monitoring; Humans; Linear Models; Models, Biological; Molecular Structure; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2007 |
The newly developed calcium antagonist, azelnidipine, increases drain volume in continuous ambulatory peritoneal dialysis patients.
Topics: Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Creatinine; Cross-Over Studies; Dihydropyridines; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Sympathetic Nervous System; Urine | 2006 |
Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine.
Topics: Aged; Amlodipine; Azetidinecarboxylic Acid; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Circadian Rhythm; Dihydropyridines; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Physicians' Offices | 2006 |
Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Amlodipine; Antioxidants; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Deoxyguanosine; Dihydropyridines; Fatty Acid-Binding Proteins; Female; Heart Rate; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Proteinuria | 2007 |
Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Azetidinecarboxylic Acid; Baroreflex; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dihydropyridines; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prospective Studies | 2007 |
Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Ascorbic Acid; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Erythrocytes; Female; Humans; Hypertension; Lipid Peroxides; Male; Middle Aged; Organophosphorus Compounds; Pyrenes; Vitamin E | 2007 |
Effects of azelnidipine on the autonomic functions and its influence on arterial stiffness and endothelial functions.
Topics: Aged; Arteries; Autonomic Pathways; Azetidinecarboxylic Acid; Brachial Artery; Calcium Channel Blockers; Cross-Over Studies; Dihydropyridines; Double-Blind Method; Endothelium, Vascular; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Pulse; Vasodilation | 2008 |
Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Azetidinecarboxylic Acid; C-Reactive Protein; Calcium Channel Blockers; Creatinine; Deoxyguanosine; Diabetic Nephropathies; Dihydropyridines; Dinoprost; Drug Therapy, Combination; Female; Humans; Interleukin-6; Male; Middle Aged; Oxidative Stress | 2008 |
Determination of azelnidipine by LC-ESI-MS and its application to a pharmacokinetic study in healthy Chinese volunteers.
Topics: Adult; Antipsychotic Agents; Azetidinecarboxylic Acid; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Dihydropyridines; Female; Humans; Isoindoles; Male; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Thiazoles | 2008 |
In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabete
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Azetidinecarboxylic Acid; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension, Renal; Kidney Function Tests; Lipids; Male; Middle Aged; Thiazepines; Treatment Outcome | 2008 |
Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Creatinine; Deoxyguanosine; Diabetic Nephropathies; Dihydropyridines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acid-Binding Proteins; Female; Follow-Up Studies; Humans; Kidney; Male; Middle Aged; Treatment Outcome | 2008 |
Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
Topics: Acetazolamide; Aged; Aged, 80 and over; Azetidinecarboxylic Acid; Blood Pressure; Brain Ischemia; Calcium Channel Blockers; Cerebrovascular Circulation; Dihydropyridines; Diuretics; Female; Humans; Hypertension; Male; Middle Aged; Positron-Emission Tomography; Regional Blood Flow | 2008 |
Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aorta; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Japan; Male; Middle Aged; Prospective Studies; Single-Blind Method; Tetrazoles; Time Factors; Treatment Outcome | 2009 |
Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography.
Topics: Adult; Aged; Aged, 80 and over; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Natriuretic Peptide, Brain; Ultrasonography; Ventricular Dysfunction, Left; Ventricular Function, Left; Young Adult | 2009 |
Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Ankle Brachial Index; Azetidinecarboxylic Acid; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Cross-Over Studies; Dihydropyridines; Diuretics; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Hypertension; Imidazoles; Lipoproteins, LDL; Male; Middle Aged; Sodium Chloride Symporter Inhibitors; Tetrazoles; Trichlormethiazide | 2009 |
Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Clinical Laboratory Techniques; Cross-Over Studies; Dihydropyridines; Female; Humans; Hypertension; Imidazoles; Individuation; Male; Middle Aged; Olmesartan Medoxomil; Population Groups; Tetrazoles | 2009 |
Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo university (ALPS-J).
Topics: Adult; Aged; Amlodipine; Azetidinecarboxylic Acid; Calcium Channel Blockers; Coronary Artery Disease; Dihydropyridines; Disease Progression; Double-Blind Method; Endpoint Determination; Female; Humans; Hypertension; Male; Middle Aged; Ultrasonography; Young Adult | 2009 |
A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asian People; Azetidinecarboxylic Acid; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dihydropyridines; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2009 |
Azelnidipine, a long-acting calcium channel blocker, could control hypertension without decreasing cerebral blood flow in post-ischemic stroke patients. A 123I-IMP SPECT follow-up study.
Topics: Aged; Azetidinecarboxylic Acid; Blood Pressure; Brain Ischemia; Calcium Channel Blockers; Cerebral Infarction; Cerebrovascular Circulation; Dihydropyridines; Female; Follow-Up Studies; Functional Laterality; Heart Rate; Humans; Hypertension; Image Processing, Computer-Assisted; Iofetamine; Male; Middle Aged; Prospective Studies; Radiopharmaceuticals; Stroke; Tomography, Emission-Computed, Single-Photon | 2010 |
Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Trichlormethiazide | 2010 |
Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dihydropyridines; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2010 |
Azelnidipine and amlodipine: a comparison of their effects and safety in a randomized double-blinded clinical trial in Chinese essential hypertensive patients.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure Monitoring, Ambulatory; China; Dihydropyridines; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Treatment Outcome | 2010 |
Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin Receptor Antagonists; Azetidinecarboxylic Acid; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Creatinine; Dihydropyridines; Dinoprost; Diuretics; Female; Humans; Imidazoles; Male; Middle Aged; Sleep; Tetrazoles | 2011 |
Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study.
Topics: Aged; Aldosterone; Antihypertensive Agents; Aorta; Azetidinecarboxylic Acid; Blood Flow Velocity; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Imidazoles; Male; Pulsatile Flow; Tetrazoles; Vascular Resistance | 2011 |
Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.
Topics: Adult; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Calcium Channel Blockers; Chronic Disease; Dihydropyridines; Female; Glycation End Products, Advanced; Humans; Hypertension; Japan; Kidney; Kidney Diseases; Male; Middle Aged; Proteinuria; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Time Factors; Treatment Outcome | 2011 |
Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J).
Topics: Amlodipine; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease; Dihydropyridines; Humans; Hypertension; Lipids; Plaque, Atherosclerotic; Ultrasonography, Interventional | 2011 |
Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action
Topics: Adult; Aged; Albuminuria; Amlodipine; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetic Nephropathies; Dihydropyridines; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Middle Aged; Research Design; Sympatholytics; Tetrazoles | 2011 |
Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Tetrazoles | 2011 |
Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Chi-Square Distribution; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Japan; Male; Middle Aged; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography | 2011 |
Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endotheli
Topics: Adult; Aged; Amlodipine; Azetidinecarboxylic Acid; Blood Glucose; Calcium Channel Blockers; Cross-Over Studies; Dihydropyridines; Endothelium, Vascular; Female; Humans; Hypertension; Inflammation; Male; Middle Aged; Prospective Studies; Stem Cells | 2011 |
Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Japan; Male; Prospective Studies; Single-Blind Method; Survival Analysis; Tetrazoles; Treatment Outcome | 2012 |
Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney disease: a randomized controlled study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Glomerular Filtration Rate; Humans; Hypertension; Male; Middle Aged; Renal Insufficiency, Chronic; Time | 2012 |
Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretic
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dihydropyridines; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Tetrazoles; Treatment Outcome | 2012 |
Association of changes in ambulatory arterial stiffness index and pulse wave velocity during antihypertensive treatment: the J-CORE study.
Topics: Aged; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure Monitoring, Ambulatory; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Pulse Wave Analysis; Tetrazoles; Vascular Stiffness | 2012 |
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Chi-Square Distribution; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heart Rate; Humans; Hypertension; Imidazoles; Japan; Male; Middle Aged; Tetrazoles; Time Factors; Treatment Outcome | 2012 |
[Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo Medical University].
Topics: Aged; Amlodipine; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Coronary Artery Disease; Dihydropyridines; Female; Humans; Hypertension; Male; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Preoperative Period; Prospective Studies; Ultrasonography, Interventional | 2012 |
Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus, Type 2; Dihydropyridines; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension; Imidazoles; Kidney Diseases; Male; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Tetrazoles; Young Adult | 2013 |
Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial.
Topics: Aged; Amlodipine; Azetidinecarboxylic Acid; Diastole; Dihydropyridines; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Male; Middle Aged; Pulse Wave Analysis; Tetrazoles; Vascular Stiffness; Ventricular Function, Left | 2013 |
Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Biomarkers; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Dihydropyridines; Diuretics; Drug Therapy, Combination; Essential Hypertension; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Matrix Metalloproteinase 2; Middle Aged; Osteoprotegerin; Prospective Studies; Tetrazoles | 2014 |
Effects of azelnidipine on uric acid metabolism in patients with essential hypertension.
Topics: Aged; Aged, 80 and over; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Creatinine; Dihydropyridines; Essential Hypertension; Female; Humans; Hypertension; Hyperuricemia; Male; Uric Acid | 2014 |
Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: a subanalysis of the OSCAR study.
Topics: Age Factors; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Asian People; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Japan; Male; Prospective Studies; Risk Factors; Sex Factors; Tetrazoles; Treatment Outcome | 2014 |
Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography, Doppler, Pulsed; Female; Follow-Up Studies; Humans; Hypertension; Hypertrophy, Left Ventricular; Image Interpretation, Computer-Assisted; Male; Middle Aged; Prospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension.
Topics: Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Baroreflex; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Dihydropyridines; Essential Hypertension; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Sympathetic Nervous System | 2014 |
Changes in left ventricular relaxation after azelnidipine treatment in hypertensive patients with diabetes: subanalysis of a prospective single-arm multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetic Cardiomyopathies; Dihydropyridines; Echocardiography; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Ventricular Dysfunction, Left; Ventricular Function, Left | 2014 |
Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial.
Topics: Aged; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Diuretics; Female; Humans; Hypertension; Japan; Male; Middle Aged; Risk Factors; Treatment Outcome; Trichlormethiazide | 2015 |
124 other study(ies) available for azelnidipine and dihydropyridines
| Article | Year |
|---|---|
Antihypertensive effect of CS-905, a novel dihydropyridine calcium blocker, in conscious hypertensive dogs.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Azetines; Calcium Channel Blockers; Dihydropyridines; Dogs; Dose-Response Relationship, Drug; Hypertension, Renal; Juxtaglomerular Apparatus; Male; Nephrectomy; Nicardipine; Renin; Renin-Angiotensin System | 1990 |
Hemodynamic changes following long-term administration of CS-905, a novel dihydropyridine calcium blocker, in conscious SHR.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Cardiac Output; Dihydropyridines; Heart Rate; Hemodynamics; Kinetics; Male; Microspheres; Rats; Rats, Inbred SHR; Regional Blood Flow; Time Factors | 1990 |
Beneficial renal effects of CS-905, a novel dihydropyridine calcium blocker, in SHR.
Topics: Acetylglucosaminidase; Animals; Azetidinecarboxylic Acid; Azetines; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Hypertension; Kidney; Kidney Glomerulus; Male; Proteinuria; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 1989 |
Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.
Topics: Anesthesia; Animals; Antihypertensive Agents; Aorta; Azetidinecarboxylic Acid; Azetines; Blood Pressure; Calcium Channel Blockers; Desoxycorticosterone; Dihydropyridines; Heart Rate; Hypertension; Hypertension, Renal; In Vitro Techniques; Male; Muscle Contraction; Muscle, Smooth, Vascular; Nephrectomy; Rats; Rats, Inbred SHR; Rats, Inbred Strains | 1989 |
[Studies of novel 1,4-dihydropyridine Ca antagonist CS-905. I. Measurement of partition coefficient (log P) by high performance liquid chromatography (HPLC)].
Topics: Animals; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Dihydropyridines; Male; Octanols; Rats; Rats, Inbred SHR; Solubility; Water | 1995 |
Effects of CS-905, a novel dihydropyridine calcium channel blocker, on arterial pressure, renal excretory function, and inner medullary blood flow in the rat.
Topics: Anesthesia; Animals; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Diuresis; Glomerular Filtration Rate; Infusions, Intravenous; Injections; Kidney; Kidney Medulla; Male; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Renal Circulation | 1994 |
Effects of dihydropyridine Ca blockers on the renal function in nephrotic spontaneously hypertensive rat (SHR).
Topics: Animals; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Glomerular Filtration Rate; Heart Rate; Hypertension; Kidney Function Tests; Male; Nephrosis; Nicardipine; Puromycin Aminonucleoside; Rats; Rats, Inbred SHR; Sodium | 1994 |
Effects of azelnidipine, a dihydropyridine calcium antagonist, on myocardial stunning in dogs.
Topics: Animals; Atropine; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Dogs; Female; Heart; Hemodynamics; Male; Myocardial Contraction; Myocardial Ischemia; Propranolol | 1998 |
Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist: beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Drug Therapy, Combination; Hypertension; Kidney; Kidney Failure, Chronic; Male; Nephrectomy; Protective Agents; Rats; Rats, Inbred SHR; Thiazepines | 2002 |
Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Occlusive Diseases; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cell Division; Dihydropyridines; Drug Synergism; Drug Therapy, Combination; Imidazoles; Inflammation; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Olmesartan Medoxomil; Oxidative Stress; Receptor, Angiotensin, Type 1; Tetrazoles; Tunica Intima | 2004 |
Biliary excretion of azelnidipine, a calcium antagonist, in rats.
Topics: Animals; Azetidinecarboxylic Acid; Bile; Calcium Channel Blockers; Cholagogues and Choleretics; Dihydropyridines; Hyperbilirubinemia; Male; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Rats; Rats, Sprague-Dawley; Sulfobromophthalein; Taurocholic Acid; Vinblastine | 2004 |
Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties.
Topics: Amlodipine; Antioxidants; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Endothelium, Vascular; Humans; In Vitro Techniques; Interleukin-8; Radioligand Assay; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor AP-1; Tumor Necrosis Factor-alpha; Umbilical Veins | 2004 |
Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells.
Topics: Angiotensin II; Animals; Aorta, Thoracic; Azetidinecarboxylic Acid; Cells, Cultured; Dihydropyridines; Dose-Response Relationship, Drug; MAP Kinase Signaling System; Muscle, Smooth, Vascular; Rats; Rats, Sprague-Dawley | 2005 |
Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cardiac Output, Low; Creatinine; Dihydropyridines; Drug Combinations; Echocardiography; Gene Expression; Hypertension; Imidazoles; Myocardium; Olmesartan Medoxomil; Organ Size; Rats; Rats, Inbred Dahl; Survival Analysis; Tetrazoles; Thiazepines | 2004 |
Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
Topics: Antihypertensive Agents; Antioxidants; Arteriosclerosis; Azetidinecarboxylic Acid; Biomarkers; Calcium; Cardiovascular Diseases; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus; Dihydropyridines; Endothelium, Vascular; Humans; Hypertension; Insulin Resistance; Interleukin-8; Models, Biological; Reactive Oxygen Species; Transcription Factor AP-1; Tumor Necrosis Factor-alpha; Umbilical Veins | 2005 |
Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Azetidinecarboxylic Acid; Blotting, Western; Calcium Channel Blockers; Cells, Cultured; Dihydropyridines; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Imidazoles; Mice; Mice, Knockout; Muscle, Smooth, Vascular; NADPH Oxidases; Olmesartan Medoxomil; Oxidative Stress; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Superoxides; Tetrazoles; Time Factors | 2005 |
Effects of calcium channel blockade on angiotensin II-induced peritubular ischemia in rats.
Topics: Adenosine Triphosphate; Angiotensin II; Animals; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Ischemia; Kidney Tubules; Male; Rats; Rats, Sprague-Dawley; Vascular Resistance | 2006 |
Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats.
Topics: Acetylglucosamine; Animals; Azetidinecarboxylic Acid; Blood Pressure; Calcium; Dihydropyridines; Glycation End Products, Advanced; Kidney Diseases; Male; Rats; Rats, Sprague-Dawley; Serum Albumin; Time Factors | 2005 |
Azelnidipine, a dihydropyridine-based calcium antagonist, inhibits angiotensin II-induced oxidative stress generation and downregulation of pigment epithelium-derived factor mRNA levels in microvascular endothelial cells.
Topics: Angiotensin II; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cells, Cultured; Dihydropyridines; Endothelial Cells; Eye Proteins; Gene Expression Regulation; Humans; Microcirculation; Nerve Growth Factors; Nitrendipine; Oxidative Stress; Reactive Oxygen Species; RNA, Messenger; Serpins | 2005 |
Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells.
Topics: Animals; Aorta, Thoracic; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cell Culture Techniques; Cells, Cultured; Dihydropyridines; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Induction; Humans; Interferon-gamma; Kinetics; Lipopolysaccharides; Male; Muscle, Smooth, Vascular; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Rats; Rats, Wistar; Umbilical Veins | 2006 |
Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Azetidinecarboxylic Acid; Baroreflex; Calcium Channel Blockers; Dihydropyridines; Hemodynamics; Kidney; Male; Nitroprusside; Phenylephrine; Rats; Rats, Inbred SHR; Sympathetic Nervous System; Vasoconstrictor Agents; Vasodilator Agents | 2005 |
Simultaneous determination of azelnidipine and two metabolites in human plasma using liquid chromatography-tandem mass spectrometry.
Topics: Adult; Azetidinecarboxylic Acid; Calcium Channel Blockers; Calibration; Chromatography, High Pressure Liquid; Dihydropyridines; Humans; Male; Quality Control; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2006 |
A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates.
Topics: Aged; Animals; Azetidinecarboxylic Acid; Calcium; Calcium Channel Blockers; Chemokine CCL2; Dihydropyridines; Female; Humans; Iliac Artery; Macaca fascicularis; Male; Middle Aged; Oxidative Stress; Stents; Treatment Outcome; Tunica Intima | 2006 |
Azelnidipine, a new calcium channel blocker, inhibits endothelial inflammatory response by reducing intracellular levels of reactive oxygen species.
Topics: Aorta; Azetidinecarboxylic Acid; Biphenyl Compounds; Calcium Channel Blockers; Cell Adhesion; Cell Membrane; Cyclic N-Oxides; Dihydropyridines; Dose-Response Relationship, Drug; Endothelial Cells; Fluoresceins; Free Radical Scavengers; Gene Expression Regulation; Humans; Hydrazines; Indicators and Reagents; Inflammation; Ketocholesterols; Monocytes; NF-kappa B p50 Subunit; Nifedipine; Picrates; Protein Transport; Reactive Oxygen Species; RNA, Messenger; Time Factors; Tumor Necrosis Factor-alpha; U937 Cells; Vascular Cell Adhesion Molecule-1 | 2006 |
The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Azetidinecarboxylic Acid; Brain Ischemia; Calcium Channel Blockers; Cerebrovascular Circulation; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Imidazoles; Male; Mice; Mice, Inbred C57BL; Tetrazoles | 2006 |
Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis.
Topics: Amlodipine; Animals; Azetidinecarboxylic Acid; Cardiomegaly; Dihydropyridines; Endomyocardial Fibrosis; Hydralazine; Hypertension; Male; Mitogen-Activated Protein Kinases; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tachycardia; Ventricular Remodeling | 2006 |
Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antimetabolites; Antioxidants; Azetidinecarboxylic Acid; Blood Glucose; Calcium Channel Blockers; Cyclic N-Oxides; Deoxyglucose; Diabetes Mellitus, Type 2; Dihydropyridines; Glucose Intolerance; Glucose Tolerance Test; Glucose Transporter Type 4; Imidazoles; Insulin; Insulin Receptor Substrate Proteins; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Phosphoproteins; Spin Labels; Superoxides; Tetrazoles | 2006 |
The actions of azelnidipine, a dihydropyridine-derivative Ca antagonist, on voltage-dependent Ba2+ currents in guinea-pig vascular smooth muscle.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Azetidinecarboxylic Acid; Barium; Calcium Channel Blockers; Dihydropyridines; Female; Guinea Pigs; Ion Channel Gating; Male; Muscle, Smooth, Vascular | 2006 |
Azelnidipine down-regulates renal angiotensin-converting enzyme and mineralocorticoid receptor mRNA in diabetic hypertensive rats.
Topics: Animals; Aorta, Thoracic; Azetidinecarboxylic Acid; Blood Pressure; Body Weight; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dihydropyridines; Down-Regulation; Heart; Hypertension; Kidney Cortex; Male; Myocardium; Organ Size; Peptidyl-Dipeptidase A; Rats; Rats, Inbred Strains; Receptors, Mineralocorticoid; Renin-Angiotensin System; RNA, Messenger | 2006 |
SDF-1-induced adhesion of monocytes to vascular endothelium is modulated by azelnidipine via protein kinase C inhibition.
Topics: Azetidinecarboxylic Acid; Blotting, Western; Calcium; Calcium Channel Blockers; Carbazoles; Cell Adhesion; Cell Adhesion Molecules; Cell Line; Cells, Cultured; Chemokine CXCL12; Chemokines, CXC; Dihydropyridines; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; Humans; Indoles; Interleukin-1beta; Ionophores; Mitogen-Activated Protein Kinases; Monocytes; Protein Kinase C-alpha | 2006 |
Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
Topics: Animals; Aorta; Azetidinecarboxylic Acid; Blood Pressure; Brain; Calcium Channel Blockers; Dihydropyridines; Enzyme Activation; Heart Rate; Male; Myocardium; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Norepinephrine; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Sympathetic Nervous System | 2007 |
Azelnidipine inhibits H2O2-induced cell death in neonatal rat cardiomyocytes.
Topics: Animals; Animals, Newborn; Azetidinecarboxylic Acid; Blotting, Western; Calcium Channel Blockers; Cell Death; Cell Survival; Cells, Cultured; Dihydropyridines; Extracellular Signal-Regulated MAP Kinases; Hydrogen Peroxide; MAP Kinase Kinase 4; Myocytes, Cardiac; Nifedipine; p38 Mitogen-Activated Protein Kinases; Rats | 2007 |
Enantioselective determination of azelnidipine in human plasma using liquid chromatography-tandem mass spectrometry.
Topics: Azetidinecarboxylic Acid; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Dihydropyridines; Humans; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism; Tandem Mass Spectrometry | 2007 |
Tilting-induced decrease in systolic blood pressure in bedridden hypertensive elderly inpatients: effects of azelnidipine.
Topics: Aged; Aged, 80 and over; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hypertension; Inpatients; Male; Posture; Systole | 2006 |
The long-acting Ca2+-channel blocker azelnidipine prevents left ventricular remodeling after myocardial infarction.
Topics: Animals; Azetidinecarboxylic Acid; Blotting, Northern; Calcium Channel Blockers; Chemokine CCL2; Collagen Type I; Collagen Type III; Dihydropyridines; Echocardiography; Gene Expression; Glyceraldehyde-3-Phosphate Dehydrogenases; Male; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Organ Size; Plasminogen Activator Inhibitor 1; Rats; Rats, Wistar; RNA, Messenger; Ventricular Function, Left; Ventricular Remodeling | 2007 |
Azelnidipine has anti-atherosclerotic effects independent of its blood pressure-lowering actions in monkeys and mice.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Chemokine CCL2; Dihydropyridines; Disease Models, Animal; Dose-Response Relationship, Drug; Macaca fascicularis; Male; Mice; Mice, Knockout; Platelet-Derived Growth Factor; Random Allocation; Tunica Intima | 2008 |
Effects of calcium channel blocker azelnidipine on experimental abdominal aortic aneurysms.
Topics: Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Disease Progression; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Rats; Rats, Wistar | 2007 |
Azelnidipine attenuates cardiovascular and sympathetic responses to air-jet stress in genetically hypertensive rats.
Topics: Administration, Oral; Animals; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Cardiovascular System; Dihydropyridines; Dose-Response Relationship, Drug; Heart Rate; Homeostasis; Hypertension; Injections, Intravenous; Male; Nicardipine; Rats; Rats, Inbred SHR; Stress, Physiological; Sympathetic Nervous System; Time Factors | 2007 |
Antioxidative effects of azelnidipine on mesangial cell proliferation induced by highly concentrated insulin.
Topics: Acetophenones; Animals; Antioxidants; Azetidinecarboxylic Acid; Blotting, Western; Calcium Channel Blockers; Cell Proliferation; Dihydropyridines; DNA; Extracellular Signal-Regulated MAP Kinases; Hypoglycemic Agents; Insulin; Mesangial Cells; Mitogen-Activated Protein Kinase 1; Oxidative Stress; Phosphorylation; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2007 |
Effect of benidipine on simvastatin metabolism in human liver microsomes.
Topics: Algorithms; Area Under Curve; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dihydropyridines; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Microsomes, Liver; Models, Biological; Molecular Structure; Simvastatin | 2007 |
Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats.
Topics: Amlodipine; Animals; Antioxidants; Apoptosis; Azetidinecarboxylic Acid; Brain; Brain Edema; Brain Infarction; Calcium Channel Blockers; Dihydropyridines; Immunohistochemistry; In Situ Nick-End Labeling; Infarction, Middle Cerebral Artery; Male; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Rats; Rats, Inbred WKY; Reperfusion Injury; Treatment Outcome | 2007 |
Spectroscopic studies on the interaction of azelnidipine with bovine serum albumin.
Topics: Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cattle; Circular Dichroism; Dihydropyridines; Protein Binding; Serum Albumin, Bovine; Spectrometry, Fluorescence; Thermodynamics | 2008 |
Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity.
Topics: 3-Iodobenzylguanidine; Adipokines; Aged; Antihypertensive Agents; Antioxidants; Arteriosclerosis; Autonomic Nervous System; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cardiomegaly; Carotid Arteries; Catecholamines; Cytokines; Dihydropyridines; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Pulse; Radionuclide Imaging; Radiopharmaceuticals | 2007 |
Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Combined Modality Therapy; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Heart Rate; Hypertension; Imidazoles; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Physical Conditioning, Animal; Rats; Rats, Inbred SHR; Regression Analysis; Sympathetic Nervous System; Tetrazoles | 2008 |
Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Calcium Signaling; Cell Movement; Cells, Cultured; Dihydropyridines; Disease Models, Animal; Equipment and Supplies; Estrenes; Hypertension; Imidazoles; Inositol 1,4,5-Trisphosphate Receptors; Macrocyclic Compounds; Muscle, Smooth, Vascular; Oxazoles; Pyrrolidinones; Rats; Rats, Wistar; Signal Transduction; Tetrazoles; Type C Phospholipases | 2008 |
Therapeutic strategy for ischemic stroke.
Topics: Animals; Azetidinecarboxylic Acid; Biliverdine; Brain Ischemia; Dihydropyridines; Free Radical Scavengers; Granulocyte Colony-Stimulating Factor; Neuroprotective Agents; Rats; Stem Cells; Stroke; Tissue Scaffolds | 2009 |
In vivo imaging of renal redox status during azelnidipine treatment.
Topics: Animals; Antioxidants; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Creatinine; Dihydropyridines; Disease Models, Animal; Electron Spin Resonance Spectroscopy; Hypertension, Renal; Kidney; Male; Mice; Mice, Inbred ICR; Oxidation-Reduction; Oxidative Stress | 2008 |
Renoprotective effect of azelnidipine in rats.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Blood Urea Nitrogen; Calcium Channel Blockers; Collagen Type III; Data Interpretation, Statistical; Dihydropyridines; HSP47 Heat-Shock Proteins; Hypertension; Immunohistochemistry; Kidney; Kidney Diseases; Kidney Function Tests; Macrophages; Male; NADPH Oxidases; Phosphopyruvate Hydratase; Rats; Rats, Inbred SHR | 2008 |
Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Antioxidants; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Heart Rate; Hydralazine; Hypertension; Male; Medulla Oblongata; NADPH Oxidases; Norepinephrine; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Superoxide Dismutase; Sympathetic Nervous System; Thiobarbituric Acid Reactive Substances | 2008 |
Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Chemokine CCL2; Dihydropyridines; Drug Synergism; Femoral Artery; Imidazoles; Ligation; Male; Mice; Mice, Inbred C57BL; NADPH Oxidases; Neuropeptides; Nifedipine; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Tunica Intima | 2009 |
Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aldosterone; Angiotensin II; Azetidinecarboxylic Acid; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cell Line, Tumor; Cytochrome P-450 CYP11B2; Dihydropyridines; Gene Expression Regulation; Humans; Nitrophenols; Organophosphorus Compounds; Potassium Chloride; Steroid 11-beta-Hydroxylase | 2009 |
Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine.
Topics: Adjuvants, Anesthesia; Amlodipine; Anesthesia; Animals; Atropine; Azetidinecarboxylic Acid; Baroreflex; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Coronary Vessels; Dihydropyridines; Dogs; Dose-Response Relationship, Drug; Heart Rate; Infusions, Intravenous; Injections, Intravenous; Pentobarbital; Perfusion; Propranolol; Sympathetic Nervous System; Time Factors | 2009 |
Combination use of immune complexes and a Ca2(+) channel blocker azelnidipine enhances interleukin-12 p40 secretion without T helper type 17 cytokine secretion in human monocyte-derived dendritic cells.
Topics: Antigen-Antibody Complex; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cells, Cultured; Dendritic Cells; Dihydropyridines; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-10; Interleukin-12; Interleukin-12 Subunit p40; Interleukin-23; Interleukin-6; Lipopolysaccharides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Tumor Necrosis Factor-alpha | 2009 |
Comparative effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Heart; Heart Atria; Imidazoles; Myocytes, Cardiac; Oxidative Stress; rac1 GTP-Binding Protein; Rats; Rats, Inbred SHR; Tetrazoles | 2009 |
Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diastole; Dihydropyridines; Heart Failure; Imidazoles; Male; Myocardium; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Tetrazoles | 2009 |
Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats.
Topics: Aldosterone; Animals; Azetidinecarboxylic Acid; Blood Pressure; Body Weight; Calcium Channel Blockers; Collagen Type IV; Connective Tissue Growth Factor; Creatinine; Dihydropyridines; Ethidium; Gene Expression; Kidney; Kidney Diseases; Male; Mesangial Cells; NADPH Oxidases; Organ Size; Proteinuria; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta | 2009 |
Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats.
Topics: Angiotensin II; Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Infusions, Intravenous; Male; Microcirculation; Nephritis, Interstitial; Nifedipine; Rats; Rats, Wistar; Renal Circulation | 2009 |
Central blood pressure under angiotensin and calcium channel blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Diuretics; Drug Therapy, Combination; Heart Rate; Humans; Hydrochlorothiazide; Imidazoles; Tetrazoles; Treatment Outcome | 2009 |
Combination of chronic exercise and antihypertensive therapy enhances renoprotective effects in rats with renal ablation.
Topics: Ablation Techniques; Actins; Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Urea Nitrogen; Combined Modality Therapy; Creatinine; Dihydropyridines; Exercise Therapy; Imidazoles; Kidney; Kidney Failure, Chronic; Male; Proteinuria; Rats; Rats, Inbred WKY; Tetrazoles | 2009 |
Beneficial effects of combination therapy with olmesartan and azelnidipine in murine polycystic kidneys.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Azetidinecarboxylic Acid; Blotting, Western; Calcium Channel Blockers; Dihydropyridines; Drug Synergism; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Imidazoles; Immunohistochemistry; Kidney; Mice; NADPH Oxidases; Nitric Oxide Synthase Type III; Polycystic Kidney Diseases; Tetrazoles | 2009 |
Cardiovascular effects of azelnidipine in comparison with those of amlodipine assessed in the halothane-anaesthetized dog.
Topics: Amlodipine; Anesthetics, Inhalation; Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Dogs; Dose-Response Relationship, Drug; Female; Halothane; Heart Rate; Heart Ventricles; Infusions, Intravenous; Male; Myocardial Contraction; Norepinephrine | 2010 |
Azelnidipine decreases plasma matrix metalloproteinase-9 levels after endovascular abdominal aortic aneurysm repair.
Topics: Aged; Aortic Aneurysm, Abdominal; Azetidinecarboxylic Acid; Blood Vessel Prosthesis Implantation; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Male; Matrix Metalloproteinase 9; Middle Aged | 2009 |
Beneficial effect of combination therapy comprising angiotensin II receptor blocker plus calcium channel blocker on plasma adiponectin levels.
Topics: Adiponectin; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Benzimidazoles; Benzoates; Calcium Channel Blockers; Cohort Studies; Dihydropyridines; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Retrospective Studies; Sex Characteristics; Telmisartan | 2010 |
Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Azetidinecarboxylic Acid; Biological Factors; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Imidazoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Signal Transduction; Streptozocin; Tetrazoles; Vasodilation | 2010 |
Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients.
Topics: Aged; Aged, 80 and over; Aldosterone; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Renin | 2010 |
Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Azetidinecarboxylic Acid; Biomarkers; C-Reactive Protein; Calcium Channel Blockers; Deoxyguanosine; Dihydropyridines; Female; Humans; Hypertension; In Vitro Techniques; Inflammation Mediators; Interleukin-6; Interleukin-8; Leukocytes, Mononuclear; Male; Middle Aged; Oxidative Stress | 2010 |
Azelnidipine-induced chyloperitoneum in a patient with microscopic polyangiitis.
Topics: Aged; Azetidinecarboxylic Acid; Calcium Channel Blockers; Chylous Ascites; Dihydropyridines; Glomerulonephritis; Humans; Kidney; Male; Microscopic Polyangiitis | 2010 |
[Enantiomeric separation of azelnidipine by high performance liquid chromatography with chiral stationary phase].
Topics: Azetidinecarboxylic Acid; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Dihydropyridines; Stereoisomerism | 2010 |
Cytokine reducing effect of azelnidipine in human peripheral blood mononuclear cells.
Topics: Azetidinecarboxylic Acid; Calcium Channel Blockers; Cytokines; Dihydropyridines; Enzyme-Linked Immunosorbent Assay; Humans; Inflammation Mediators; Monocytes | 2010 |
Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property.
Topics: Adipocytes; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cells, Cultured; Dihydropyridines; Down-Regulation; Glycation End Products, Advanced; Humans; Imidazoles; Oxidative Stress; RNA, Messenger; Tetrazoles | 2011 |
Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage.
Topics: Animals; Azetidinecarboxylic Acid; Biomarkers; Blood Glucose; Calcium Channel Blockers; Catalase; Cytokines; Diabetes Mellitus, Experimental; Dihydropyridines; Glutathione; Heart Diseases; Homocysteine; Inflammation Mediators; Insulin; Lipid Peroxidation; Lipids; Liver; Male; Myocardium; Oxidative Stress; Protein Carbonylation; Rats; Rats, Wistar; Superoxide Dismutase | 2010 |
Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Dihydropyridines; Drug Therapy, Combination; Hydrochlorothiazide; Imidazoles; Kidney Diseases; Oxidative Stress; Rats; Rats, Inbred SHR; Tetrazoles; Vascular Diseases | 2011 |
Reduction of albuminuria with antihypertensive treatment: is more always better?
Topics: Albuminuria; Antihypertensive Agents; Azetidinecarboxylic Acid; Dihydropyridines; Humans; Hydrochlorothiazide; Imidazoles; Tetrazoles | 2011 |
Azelnidipine, a new calcium channel blocker, promotes skin wound healing in diabetic rats.
Topics: Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Dihydropyridines; Disease Models, Animal; Male; Nitric Oxide; Nitrites; Rats; Skin; Streptozocin; Wound Healing | 2011 |
Comparative effects of azelnidipine and amlodipine on myocardial function and mortality after ischemia/reperfusion in dogs.
Topics: Amlodipine; Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Dog Diseases; Dogs; Energy Metabolism; Female; Male; Myocardium; Reperfusion Injury | 2011 |
L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dihydropyridines; Female; Humans; Hypertension; Imidazoles; Male; Tetrazoles | 2011 |
Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence.
Topics: Angiotensin II; Animals; Antioxidants; Azetidinecarboxylic Acid; Calcium; Calcium Channel Blockers; Carbon Tetrachloride; Cell Line; Cell Survival; Collagen Type I; Collagen Type I, alpha 1 Chain; Dihydropyridines; Disease Models, Animal; Gene Expression Regulation; Humans; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Reactive Oxygen Species; RNA, Messenger; Thioacetamide; Transforming Growth Factor beta1 | 2012 |
Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis.
Topics: Animals; Antioxidants; Apoptosis; Azetidinecarboxylic Acid; Calcium; Calcium Channel Blockers; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Dihydropyridines; Male; Myocardial Contraction; Myocardium; Oxidative Stress; Phosphoproteins; Rats; Rats, Wistar; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Superoxides; Time Factors; Troponin I; Ventricular Dysfunction, Left; Ventricular Function, Left | 2011 |
Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity.
Topics: Amlodipine; Animals; Arterioles; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Heart Rate; Kidney Diseases; Kidney Glomerulus; Male; Rats; Rats, Inbred Dahl; Sympathectomy; Sympathetic Nervous System | 2012 |
Mechanistic study on degradation of azelnidipine solution under radical initiator-based oxidative conditions.
Topics: Azetidinecarboxylic Acid; Chemistry, Pharmaceutical; Dihydropyridines; Free Radicals; Oxidation-Reduction; Oxidative Stress; Pharmaceutical Solutions | 2012 |
Azelnidipine, unique calcium channel blocker could prevent stress-induced cardiac dysfunction like α·β blocker.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Echoencephalography; Heart Rate; Labetalol; Male; Rats; Rats, Sprague-Dawley; Restraint, Physical; Stress, Psychological; Takotsubo Cardiomyopathy; Ventricular Function, Left | 2012 |
Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Oxidative Stress; Rats; Rats, Inbred SHR; Tetrazoles | 2012 |
Calcium antagonist added to angiotensin receptor blocker: a recipe for reducing blood pressure variability?: evidence from day-by-day home blood pressure monitoring.
Topics: Azetidinecarboxylic Acid; Blood Pressure; Dihydropyridines; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Tetrazoles | 2012 |
Solid state characterizations and analysis of stability in azelnidipine polymorphs.
Topics: Azetidinecarboxylic Acid; Calcium Channel Blockers; Calorimetry, Differential Scanning; Dihydropyridines; Drug Stability; Kinetics; Powder Diffraction; Solubility; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Thermodynamics | 2012 |
Hypertension in older adults: progress and limitations.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hypertension; Imidazoles; Male; Tetrazoles | 2012 |
Azelnidipine inhibits Msx2-dependent osteogenic differentiation and matrix mineralization of vascular smooth muscle cells.
Topics: Alkaline Phosphatase; Azetidinecarboxylic Acid; Calcification, Physiologic; Calcium Channel Blockers; Cell Differentiation; Cells, Cultured; Dihydropyridines; DNA Primers; Gene Expression; Homeodomain Proteins; Humans; Muscle, Smooth, Vascular; Osteogenesis; Real-Time Polymerase Chain Reaction; Transfection; Vascular Calcification | 2012 |
Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Apolipoproteins E; Atherosclerosis; Azetidinecarboxylic Acid; Azo Compounds; Blood Pressure; Body Weight; Calcium Channel Blockers; Coronary Vessels; Diabetes Mellitus, Experimental; Dihydropyridines; Drug Therapy, Combination; Imidazoles; Macrophages; Male; Mice; Mice, Inbred C57BL; Models, Biological; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphorylation; Systole; Tetrazoles | 2012 |
Atypical drug-induced hypersensitivity syndrome with human herpesvirus 6 reactivation due to calcium blockers.
Topics: Aged; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Drug Hypersensitivity Syndrome; Herpesvirus 6, Human; Humans; Male; Roseolovirus Infections; Virus Activation | 2013 |
The pharmacological differences in antianginal effects of long-lasting calcium channel blockers: azelnidipine and amlodipine.
Topics: Administration, Oral; Amlodipine; Angina Pectoris; Animals; Arginine Vasopressin; Azetidinecarboxylic Acid; Blood Pressure; Calcium; Calcium Channel Blockers; Coronary Vessels; Dihydropyridines; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Heart Rate; Male; Myocardium; Oxygen Consumption; Rats; Swine; Time Factors; Vasoconstriction | 2013 |
Inhibitory effects of azelnidipine tablets on morning hypertension.
Topics: Aged; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Dihydropyridines; Female; Humans; Hypertension; Male; Middle Aged; Registries; Tablets; Treatment Outcome | 2013 |
Study of sustained blood pressure-lowering effect of azelnidipine guided by self-measured morning and evening home blood pressure: subgroup analysis of the At-HOME study.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Dihydropyridines; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Time Factors; Treatment Outcome; Young Adult | 2013 |
Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects.
Topics: Aminopropionitrile; Angiotensin II; Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Aneurysm, Abdominal; Aortic Aneurysm, Thoracic; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Disease Progression; Inflammation Mediators; Macrophages; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Sirtuin 1; Time Factors; Tumor Necrosis Factor-alpha | 2013 |
Simultaneous treatment with azelnidipine and olmesartan inhibits apoptosis of Hl-1 cardiac myocytes expressing E334k cMyBPC.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Azetidinecarboxylic Acid; bcl-X Protein; Calcium Channel Blockers; Carrier Proteins; Cells, Cultured; Dihydropyridines; Imidazoles; Mice; Myocytes, Cardiac; Proto-Oncogene Proteins c-bcl-2; Tetrazoles | 2013 |
Effect of azelnidipine and amlodipine on single cell mechanics in mouse cardiomyocytes.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Animals; Azetidinecarboxylic Acid; Biomechanical Phenomena; Calcium Channel Blockers; Dihydropyridines; Drug Interactions; Imidazoles; Mechanical Phenomena; Mice; Myocytes, Cardiac; Single-Cell Analysis; Tetrazoles | 2013 |
Vasorelaxation induced by new third-generation dihydropyridine calcium antagonist azelnidipine in human internal mammary artery.
Topics: Azetidinecarboxylic Acid; Calcium Channel Blockers; Coronary Artery Bypass; Dihydropyridines; Female; Humans; In Vitro Techniques; Male; Mammary Arteries; Middle Aged; Vasoconstriction; Vasodilation | 2013 |
Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Calcium Channel Blockers; Chemokine CCL2; Dihydropyridines; Hypertension; Imidazoles; Inhibitor of Apoptosis Proteins; Kidney; Lipoproteins, LDL; Macrophages; Male; Nephrosclerosis; Olmesartan Medoxomil; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Scavenger; Tetrazoles | 2013 |
Invited commentary.
Topics: Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Male; Mammary Arteries; Vasoconstriction; Vasodilation | 2013 |
Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats.
Topics: Age Factors; Animals; Azetidinecarboxylic Acid; Blood Pressure; Brain Injuries; Chemokine CCL2; Collagen Type IV; Dihydropyridines; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation; Heart Rate; Imidazoles; Laser-Doppler Flowmetry; Male; Matrix Metalloproteinase 9; Motor Activity; Oxidative Stress; Rats; Rats, Inbred SHR; Stroke; Tetrazoles | 2014 |
Azelnidipine inhibits cultured rat aortic smooth muscle cell death induced by cyclic mechanical stretch.
Topics: Animals; Anthracenes; Antioxidants; Aorta; Azetidinecarboxylic Acid; Blood Pressure; Cells, Cultured; Dihydropyridines; Enzyme Inhibitors; Imidazoles; JNK Mitogen-Activated Protein Kinases; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Onium Compounds; p38 Mitogen-Activated Protein Kinases; Pyridines; Rats; Rats, Sprague-Dawley | 2014 |
Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Azetidinecarboxylic Acid; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Combinations; Drug Costs; Drug Substitution; Female; Humans; Hypertension; Imidazoles; Male; Medication Adherence; Middle Aged; Nephrology; Patient Satisfaction; Practice Patterns, Physicians'; Renal Insufficiency, Chronic; Retrospective Studies; Surveys and Questionnaires; Telmisartan; Tetrazoles; Valsartan | 2015 |
Regression of glomerular and tubulointerstitial injuries by dietary salt reduction with combination therapy of angiotensin II receptor blocker and calcium channel blocker in Dahl salt-sensitive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Combined Modality Therapy; Cytokines; Diet, Sodium-Restricted; Dihydropyridines; Drug Evaluation, Preclinical; Gene Expression; Gene Expression Regulation; Hypertension; Imidazoles; Kidney Glomerulus; Male; NADPH Oxidases; Rats, Inbred Dahl; Receptors, Mineralocorticoid; Renal Insufficiency; Tetrazoles | 2014 |
A liquid chromatography-tandem mass spectrometric assay for the antihypertensive agent azelnidipine in human plasma with application to clinical pharmacokinetics studies.
Topics: Adult; Antihypertensive Agents; Azetidinecarboxylic Acid; Chromatography, High Pressure Liquid; Dihydropyridines; Humans; Linear Models; Male; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Young Adult | 2015 |
Acute effects of intravenous nifedipine or azelnidipine on open-loop baroreflex static characteristics in rats.
Topics: Administration, Intravenous; Animals; Azetidinecarboxylic Acid; Baroreflex; Blood Pressure; Calcium Channel Blockers; Carotid Sinus; Dihydropyridines; Male; Nifedipine; Pressoreceptors; Rats; Rats, Inbred WKY | 2015 |
Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Dihydropyridines; Glucose; Insulin; Mice; Oxidative Stress; Phosphorylation; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Receptor, Insulin; Signal Transduction | 2015 |
Medication-taking behavior in hypertensive patients with a single-tablet, fixed-dose combination in Japan.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Azetidinecarboxylic Acid; Cohort Studies; Dihydropyridines; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Japan; Male; Medication Adherence; Middle Aged; Prospective Studies; Surveys and Questionnaires; Tablets; Tetrazoles | 2016 |
Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study.
Topics: Aged; Alanine Transaminase; Amlodipine; Antihypertensive Agents; Aspartate Aminotransferases; Azetidinecarboxylic Acid; Benzimidazoles; Biphenyl Compounds; Blood Urea Nitrogen; Cohort Studies; Creatinine; Dihydropyridines; Drug Combinations; Female; Glomerular Filtration Rate; Humans; Hypertension; Male; Middle Aged; Olmesartan Medoxomil; Potassium; Propensity Score; Retrospective Studies; Sodium; Tetrazoles; Uric Acid | 2016 |
Effects of azelnidipine and amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Autonomic Nervous System; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Essential Hypertension; Exercise; Female; Humans; Hypertension; Male; Middle Aged; Pupil | 2016 |
Olmesartan with azelnidipine versus with trichlormethiazide on home blood pressure variability in patients with type II diabetes mellitus.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cross-Over Studies; Diabetes Mellitus, Type 2; Dihydropyridines; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Pilot Projects; Tetrazoles; Trichlormethiazide | 2017 |
Solid state characterization of azelnidipine-oxalic acid co-crystal and co-amorphous complexes: The effect of different azelnidipine polymorphs.
Topics: Azetidinecarboxylic Acid; Calorimetry, Differential Scanning; Crystallization; Dihydropyridines; Drug Stability; Oxalic Acid; Powder Diffraction; Powders; Solubility; Solvents; Spectroscopy, Fourier Transform Infrared; Thermodynamics; X-Ray Diffraction | 2017 |
Inhibitory effects of losartan and azelnidipine on augmentation of blood pressure variability induced by angiotensin II in rats.
Topics: Angiotensin II; Animals; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Dose-Response Relationship, Drug; Hypertension; Losartan; Male; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Time Factors | 2017 |
Azelnidipine is a useful medication for the treatment of heart failure preserved ejection fraction.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Echocardiography; Female; Heart Failure; Heart Rate; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Radionuclide Imaging; Renin-Angiotensin System; Stroke Volume | 2017 |
Chemokines protect vascular smooth muscle cells from cell death induced by cyclic mechanical stretch.
Topics: Animals; Azetidinecarboxylic Acid; Blotting, Western; Cell Death; Cells, Cultured; Chemokine CX3CL1; Chemokine CXCL1; Computational Biology; Dihydropyridines; Imidazoles; Immunohistochemistry; Male; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Stress, Mechanical; Tetrazoles | 2017 |
Effect of Switching from Cilnidipine to Azelnidipine on Cardiac Sympathetic Nerve Function in Patients with Heart Failure Preserved Ejection Fraction.
Topics: Adult; Aged; Aged, 80 and over; Azetidinecarboxylic Acid; Calcium Channel Blockers; Dihydropyridines; Dose-Response Relationship, Drug; Drug Substitution; Echocardiography; Female; Follow-Up Studies; Heart; Heart Failure; Humans; Male; Middle Aged; Radionuclide Imaging; Retrospective Studies; Stroke Volume; Sympathetic Nervous System; Treatment Outcome | 2018 |
Azelnidipine Inhibits the Differentiation and Activation of THP-1 Macrophages through the L-Type Calcium Channel.
Topics: Azetidinecarboxylic Acid; Calcium Channels, L-Type; Cell Adhesion; Cell Differentiation; Cells, Cultured; Dihydropyridines; Humans; Macrophage Activation; Macrophages | 2018 |
Limonin alleviates macro- and micro-vascular complications of metabolic syndrome in rats: A comparative study with azelnidipine.
Topics: Animals; Aorta, Thoracic; Azetidinecarboxylic Acid; Blood Pressure; Dihydropyridines; Dose-Response Relationship, Drug; Fructose; Glycation End Products, Advanced; Hypertension; Insulin Resistance; Limonins; Male; Metabolic Syndrome; Rats | 2018 |
Azelnidipine Attenuates the Oxidative and NFκB Pathways in Amyloid-β-Stimulated Cerebral Endothelial Cells.
Topics: Amyloid beta-Peptides; Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cell Line, Transformed; Cerebral Amyloid Angiopathy; Cerebral Cortex; Dihydropyridines; Endothelial Cells; Mice; NF-kappa B; Oxidative Stress; Signal Transduction | 2019 |
Core-in-cup/liquisol dual tackling effect on azelnidipine buccoadhesive tablet micromeritics, in vitro release, and mucoadhesive strength.
Topics: Acrylic Resins; Adhesives; Administration, Buccal; Azetidinecarboxylic Acid; Biological Availability; Carboxymethylcellulose Sodium; Cellulose; Chitosan; Delayed-Action Preparations; Dihydropyridines; Drug Delivery Systems; Mouth Mucosa; Polymers; Solubility; Tablets | 2019 |
Improved bioavailability of Azelnidipine gastro retentive tablets-optimization and in-vivo assessment.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Bicarbonates; Biological Availability; Blood Pressure; Dihydropyridines; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Gastric Acid; Gastric Mucosa; Half-Life; Humans; Polyethylene Glycols; Potassium Compounds; Rabbits; Tablets | 2019 |
Efficacy and safety of a combination antihypertensive drug (olmesartan plus azelnidipine): "Issues with hypertension studies in real-world practice".
Topics: Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dihydropyridines; Drug Combinations; Drug Substitution; Female; Humans; Hypertension; Imidazoles; Japan; Male; Middle Aged; Prospective Studies; Tetrazoles; Treatment Outcome | 2020 |
Chronological Delivery of Antihypertensive Drugs in Bilayered Core-in-Cup Buccoadhesive Tablets: In Vitro and In Vivo Evaluation.
Topics: Adult; Antihypertensive Agents; Azetidinecarboxylic Acid; Biological Availability; Delayed-Action Preparations; Dihydropyridines; Drug Compounding; Humans; Imidazoles; Male; Tablets; Tetrazoles | 2019 |
Azelnidipine treatment reduces the expression of Ca
Topics: Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Calcium Channels, L-Type; Cells, Cultured; Dihydropyridines; Gene Expression Regulation; HEK293 Cells; Humans; Muscle, Smooth, Vascular; Pulmonary Artery; Rats | 2021 |
Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy.
Topics: Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; CD47 Antigen; Cell Line, Tumor; Cricetinae; Dihydropyridines; Disease Models, Animal; Drug Repositioning; Gene Expression Regulation, Neoplastic; Humans; Immunity, Innate; Immunotherapy; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Molecular Targeted Therapy; Neoplasms; Receptors, Immunologic; Receptors, Virus; T-Lymphocytes | 2021 |
Azelnidipine Exhibits In Vitro and In Vivo Antiviral Effects against Flavivirus Infections by Targeting the Viral RdRp.
Topics: Animals; Antiviral Agents; Azetidinecarboxylic Acid; Dengue; Dihydropyridines; Flavivirus; Flavivirus Infections; Mice; Molecular Docking Simulation; RNA-Dependent RNA Polymerase; Zika Virus; Zika Virus Infection | 2022 |
Evaluation of photostability of azelnidipine tablets and structure determination of its photoproducts.
Topics: Chromatography, High Pressure Liquid; Dihydropyridines; Photolysis; Spectrometry, Mass, Electrospray Ionization; Tablets | 2023 |